A COMPARISON STUDY OF PYRAN AND PYRAN NANOPARTICLES INHIBITORY EFFECT ON AMPC BETA-LACTAMASE PRODUCING KLEBSIELLA ISOLATES

Background and Aim:The prevalence of extended spectrum beta-lactamses (ESBLs)-producing strain and their resistance to beta-lactam antibiotics has had a daily increase.Recent years have witnessed unprecedented growth of research and applications in the area of nanotechnology. There is increasing optimism that nanotechnology, as applied to medicine, will bring significant advances in the treatment of disease.Methods:This study was performed on 105 clinical Klebsiella isolates. Antimicrobial susceptibility was performed using Kirby-Bauer disk diffusion method against cefepime, ceftazidime, ceftriaxon and cefotaxime. These isolates were also tested for ESBLs production by phenotypic confirmatory test (PCT). MIC of pyran and pyran nanoparticles were determined using sterile 2ml 96-well plates. The tested dilutions ranged from 2500 to 9.76 μg/mL using dimethyl sulfoxide (DMSO) as solvent. MBC was determined by subculturing the contents of wells that showed no visible growth of bacteria onto Muller Hinton agar plates and incubating at 37°C for 18 h.Results:ESBLs screening of strains by phenotypic combined disc test showed that out of 105 samples 13% (14) were ESBLs positive. ESBLs-producing isolates were tested for MIC valus. Pyran and pyran nanoparticles showed antibacterial activity with MIC values of 312.5 and 154.25 μg/mL respectively. Furthermore MBC pyran and pyran nanoparticles were 1250 and 312.5 μg/mL respectively.Conclusion:It should be mentioned that although nanoparticles is effective against bacteria in vitro, these concentrations may not have the same impacts in clinical conditions. However, further studies at the fundamental, biological, and pharmacological level are required to enable systemic administration of these antimicrobials.

Keywords:

Klebsiella , ESBLs , nanoparticles